CAPECITABINE EFFICACY WITH ADJUVANT RADIOTHERAPY IN THE TREATMENT OF EARLY STAGE BREAST CANCER (RETROSPECTIVE STUDY)
Mohamed, R., Ali, S., Eid, S. (2023). CAPECITABINE EFFICACY WITH ADJUVANT RADIOTHERAPY IN THE TREATMENT OF EARLY STAGE BREAST CANCER (RETROSPECTIVE STUDY). EKB Journal Management System, 46(2), 1033-1045. doi: 10.21608/bfsa.2023.327555
Rehab F Mohamed; Seham Adel Ali; Samir Eid. "CAPECITABINE EFFICACY WITH ADJUVANT RADIOTHERAPY IN THE TREATMENT OF EARLY STAGE BREAST CANCER (RETROSPECTIVE STUDY)". EKB Journal Management System, 46, 2, 2023, 1033-1045. doi: 10.21608/bfsa.2023.327555
Mohamed, R., Ali, S., Eid, S. (2023). 'CAPECITABINE EFFICACY WITH ADJUVANT RADIOTHERAPY IN THE TREATMENT OF EARLY STAGE BREAST CANCER (RETROSPECTIVE STUDY)', EKB Journal Management System, 46(2), pp. 1033-1045. doi: 10.21608/bfsa.2023.327555
Mohamed, R., Ali, S., Eid, S. CAPECITABINE EFFICACY WITH ADJUVANT RADIOTHERAPY IN THE TREATMENT OF EARLY STAGE BREAST CANCER (RETROSPECTIVE STUDY). EKB Journal Management System, 2023; 46(2): 1033-1045. doi: 10.21608/bfsa.2023.327555

CAPECITABINE EFFICACY WITH ADJUVANT RADIOTHERAPY IN THE TREATMENT OF EARLY STAGE BREAST CANCER (RETROSPECTIVE STUDY)

Bulletin of Pharmaceutical Sciences Assiut University
Volume 46, Issue 2, December 2023, Page 1033-1045  XML PDF (727.12 K)
Document Type: Original Article
DOI: 10.21608/bfsa.2023.327555
View on SCiNiTO View on SCiNiTO
Authors
Rehab F Mohamed email orcid 1; Seham Adel Ali2; Samir Eid1
1Clinical Oncology Department, Faculty of Medicine, Assiut University, Assuit, Egypt
2Radiotherapy Department, South Egypt Cancer Institute, Assiut University, Assuit, Egypt
Abstract
Objectives: Our goal is to assess the effectiveness and toxicity of capecitabine as radio-sensatizer with adjuvant radiotherapy in breast cancer (BC) patients. Methods: On the radiation days, the patients got capecitabine 825 mg/m2 every 12 hours with a 25% dosage reduction if creatinine clearance was lower than 30 ml/min with radiation therapy of dose of 4240 cGy administered in 16 fractions at a rate of 2.65 Gy each over the course of three weeks. In addition, a boost dose of 14 Gy administered in 7 fractions was added to the lumpectomy bed. Results: Study group were evaluated at 3, 12, 24, 36, 48, and 60 months. At 3 and 12 months, 29 patients (61.7%) exhibited G1 skin hyperpigmentation. At 60-month, 3 patients (7.5%) had G2 lymphedema (p = 0.226). At 24th month, 4 patients (9.3%) had G1 telangiectasia, 5 patients (11.6%) developed G1 skin fibrosis (p = 0.001).  Moreover, one patient (2.3%) experienced a G1 cardiac event (p = 0.416). At 3 month radiation pneumonitis G1 was identified in 3 patients (6.4%) (p = 0.416). Despite the fact that 6 patients (15%) developed distant metastases, there were no instances of local recurrence. the OS rate was 85.1%. Conclusion: Adjuvant radiation combined with capecitabine is well tolerated and effective
Keywords
radio-sensitizer; capecitabine; efficiency; breast cancer
Statistics
Article View: 94
PDF Download: 135